Navigation Links
US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
Date:2/28/2008

US ONCOLOGY HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(in thousands)

Three Months

Three Months Ended Ended

December 31, September 30,

2007 2006 2007

Product revenue $509,914 $462,184 $488,017

Service revenue 261,656 259,400 255,797

Total revenue 771,570 721,584 743,814

Cost of products 497,290 460,725 478,628

Cost of services:

Operating compensation and benefits 122,100 114,341 121,289

Other operating costs 73,755 70,256 73,177

Depreciation and amortization 18,569 17,854 19,215

Total cost of services 214,424 202,451 213,681

Total cost of products and services 711,714 663,176 692,309

General and administrative expenses 20,668 17,488 20,210

Impairment and restructuring charges 6,771 - 960

Depreciation and amortization 4,887 3,806 4,024

744,040 684,470 717,503

Income from operations 27,530 37,114 26,311

Other income (expense):

Interest expense, net (36,913) (29,547) (34,414)

Minority interests (1,743) (660) (539)

Other income (expense) (11,573) - (312)

Income (loss) before income taxes (22,699) 6,907 (8,954)

Income tax benefit (provision) 7,869 (3,654)
'/>"/>

SOURCE US Oncology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. PRA International to Present Audioconference on Oncology Research - Nov. 8
7. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
8. AG Mednet to Provide Image Network for Southwest Oncology Group
9. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
10. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
11. Oncology Metrics and Cureline Announce Joint Marketing Agreement

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...24/PRNewswire-FirstCall/-HamiltonThorneLtd.(TSX-V:...advancedlasersystemsandinstrumentsforthestemcellre...tionalandfinancialresultsforthethirdquarterendedSe...1.46millioncomparedwith$1.43millioninQ32008,-Gross...nQ3,2008,-Netlossreducedto$148,000comparedto$283,0...
(Date:11/24/2009)...--HealthRoboticstodayannounced,thatithasformedanew....ThisrecentlyformedToronto-basedcompanywilloperate...t,install,andsupport,HealthRobotics,i.v.RoomoftheF...offeringsi.v.STATION(TM),i.v.SOFT(TM),andOMM(TM).,...nan"asneeded,basis"toitsstrategicpartnershipswithM...
(Date:11/23/2009)...vocative new study, a University of Utah scientist...major cause of global warming cannot be stabilize...builds the equivalent of one new nuclear power pla...ll be any substantial near-term departure from rec...sion rates," says the new paper by Tim Garrett, an...
(Date:11/23/2009)...ire-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasdaq: PDL...7,2009astheex-dividenddateforits$200millionspecial...ontransactioncompletedonNovember2,2009.Thedividend...rdontherecorddate,December1,2009.NASDAQhassettheap...eofcommonstockforpurposesoftheex-dividenddateonNov...
Breaking Biology Technology:Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2
... , , , , Multiporator / Electr... , , , Transformation... 01/2002 , , , , , ,... Microorganism , Pseudomonas aer...ype , Bacteria, gram negative, ...
... , , , , Multiporator / Electr... , , , Transformatio... 01/2002 , , , , , ,... Microorganism , Nocardia cora...e , Bacteria, gram positive, ,...
... , , , , Multiporator / Electr... , , , Transformatio... 03/2002 , , , , , ,... Microorganism , Mycobacterium... Cell type , Bacteria, gram positive,...
Other Biology Technology:Pseudomonas aeruginosa 2Nocardia corallina 2Mycobacterium smegmatis 2
(Date:11/23/2009)...160 participants gathered this week for the sevent...E conference. This year,s topic, "Synthetic Biolog...dical researchers to explore the engineering, scie... field of synthetic biology. , Bonnie L. Bassler...ersity and this year,s conference chair, challenge...
(Date:11/23/2009)...e vaccine available for the H1N1 virus has been se...us. The vaccination marks the first time vaccine h...ndemic flu., Iowa State University,s Hank Harris...ne this summer and has been shipping preventive do...s for several weeks., The latest vaccines were s...
(Date:11/23/2009)...study by University of Alabama at Birmingham (UAB)...co-existing medical conditions (co-morbidity) do n...frican-Americans compared to Caucasians who also h...v. 23 in Cancer , a journal of the American Cance... BMI and co-morbidity are independent predictors o...
Breaking Biology News(10 mins):Synthetic biology offers new opportunities for interdisciplinary collaboration 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance 28TM 29 for Treatment of Acute Pain and Fever 51749 1Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance 28TM 29 for Treatment of Acute Pain and Fever 51749 2Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance 28TM 29 for Treatment of Acute Pain and Fever 51749 3Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance 28TM 29 for Treatment of Acute Pain and Fever 51749 4Physician Hospitals 28PHA 29 Responds to TIME Magazine Article 3A Filled With Incorrect Assumption and Innuendo 51747 1Physician Hospitals 28PHA 29 Responds to TIME Magazine Article 3A Filled With Incorrect Assumption and Innuendo 51747 2Physician Hospitals 28PHA 29 Responds to TIME Magazine Article 3A Filled With Incorrect Assumption and Innuendo 51747 3Physician Hospitals 28PHA 29 Responds to TIME Magazine Article 3A Filled With Incorrect Assumption and Innuendo 51747 4China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 1China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 2China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 3China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 4China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 5China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 6China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 7China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 8China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 9China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 10China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 11China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 12China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 13
...p elucidate mechanisms of wake-sleep transitions a...sity of Pennsylvania School of Medicine have demon...called astrocytes are directly involved in regulat...ng of the study is that astrocytes modulate the le...h is thought to be important in controlling wake-t...
...scientists at UCSF sheds light on how the odor det...eir social behavior. , "Understanding how mice pr...tes the sense of smell--should provide insight int... use to transform sensory information into behavio...SF assistant professor of anatomy. , "There are s...
...ldiers guarding a castle gate, multiple genetic de...owdery mildew disease, according to a new study. P...ts that attacks more than 9,000 species, including...tural plants such as roses and cucumbers. The rese...ein of the Carnegie Institution,s Department of Pl...
Other Biology News:Penn study finds direct role for glial cells in brain cross-talk 2New study examines how sense of smell affects mating and aggression in mice 2Genetic defenders protect crops from fungal disease 2Genetic defenders protect crops from fungal disease 3
Acridine orange, hemizinc salt from Research Organics, Inc.
Acridine orange 10-nonyl bromide from AnaSpec
Anti-rat Ig HRP detection kit from BD Biosciences Pharmingen
Wash Solution from CHEMICON
Biology Products: